Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 1, 2003, Pages 18-29

  Sanne, Ian ^a,e   Piliero, Peter ^b   Squires, Kathleen ^c   Thiry, Alexandra ^d   Schnittman, Steven ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ALBANY MEDICAL COLLEGE   (United States)

^c LAC USC MEDICAL CENTER   (United States)

^d BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^e WHC Infect Dis Clin Trials Unit   (South Africa)

Author keywords

Atazanavir; Dyslipidemia; HAART; Nelfinavir; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; DIDANOSINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY LIVER; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFECTION; INFLUENZA; JAUNDICE; LACTIC ACIDOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS TITRATION; VOMITING;

EID: 0037234238     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200301010-00004     Document Type: Article

References (48)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997;349:1294.
2. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
3. Haubrich R, Thompson M, Schooley R, et al. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS 1999;13:2411-20.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
5. Montaner JSG, Reiss P, Cooper D, et al. A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998;279:930-7.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Bangsberg DR, Perry S, Charlebois ED, et al. Adherence to HAART predicts progression in AIDS [abstract 483]. Presented at the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/483.htm. Accessed February 21, 2001.
8. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6.
9. Benson JO, McGhee K, Coplan P, et al. Fat redistribution in indinavir-treated patients with HIV infection: a review of postmarketing cases. J Acquir Immune Defic Syndr 2000;25:130-9.
10. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
11. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(Suppl):F51-8.
12. Moyle GJ, Baldwin C. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy [letter]. J Acquir Immune Defic Syndr 1999;21:423-4.
13. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
14. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-7.
15. Gao X, Nau DP, Rosenbluth SA, et al. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000;12:387-98.
16. Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001;13:27-40.
17. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother 2000;34:703-9.
18. Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999;13(Suppl A):S189-204.
19. Gong Y-F, Robinson B, Rose R, et al. Antiviral activity and resistance profile of an HIV-1 protease inhibitor BMS-232632 [abstract 1-79]. In Proceedings of the 38th Interscience Conference on Antimicrobial Agents Chemother, San Diego, September 1998. Herndon, VA: ASM Press.
20. Rabasseda X, Silvestre J, Castañer J. BMS-232632. Drugs of the Future 1999;24:375-80.
21. Squires K, Gatell J, Piliero P, et al. AI424-007: 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632 [abstract 15]. Presented at the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001. Available at: http://www.retroconference. org/2001/abstracts/abstracts/abstracts/15.htm. Accessed March 14, 2001.
22. Sanne I, Piliero P, Wood R, et al. Safety and antiviral efficacy of a once-daily HIV-1 protease inhibitor BMS-232632: 24-week results from a phase II clinical trial [abstract 691]. In Proceedings of the 40th Interscience Conference on Antimicrobial Agents Chemother, Toronto, September 2000. Herndon, VA: ASM Press.
23. Sanne I, Piliero P, Wood R, et al. Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor BMS-232632: preliminary results from a phase II clinical trial [abstract 672]. Presented at the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January-February 2000. Available at: http://www.retroconference.org/2000/abstracts/672.htm. Accessed September 27, 2000.
24. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract 504]. Presented at the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January-February 2000. Available at: http://www. retroconference.org/2000/abstracts/504.htm. Accessed October 2, 2000.
25. O'Mara EM, Smith J, Olsen SJ, et al. BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers [abstract 604]. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January-February 1999. Available at: http://www.retroconference. org/99/abstracts/604.htm. Accessed October 12, 2001.
26. Gong Y-F, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000;44:2319-26.
27. Piliero P. The utility of inhibitory quotients in determining relative potency of protease inhibitors. AIDS 2002;16:799-800.
28. Cahn P, Pantaleo G, Gatell J, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile. Presented at the XIVth World Congress of Cardiology, Sydney, May 2002.
29. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-3.
30. Haas DW, Zala C, Schrader S, et al. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48) [abstract 42]. Presented at the Ninth Conference for Retroviruses and Opportunistic Infections, Seattle, February 2002. Available at: http://63.126.3. 84/2002/Abstract/13797.htm. Accessed March 13, 2002.
31. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23.
32. Dubé MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-24.
33. D'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000;14:499-507.
34. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45.
35. Pratt DS, Kaplan MM. Evaluation of liver function. In Braunwald E. Fauci AS, Kasper DL, et al., eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 2002:1711-5.
36. O'Mara EM, Mummaneni V, Randall D, et al. Assessment of the effect of uridine diphosphate glucuronosyltransferase (UDP-GT) 1A1 genotype on indirect bilirubin elevations in healthy subjects dosed with BMS-232632 [abstract]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 2000. Available at: http://www.asmusa. org/memonly/abstracts/abstractsearch.asp.
37. Kaplan M, Hammerman C, Rubaltelli FF, et al. Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology 2002;35:905-11.
38. Zucker S, Qin X, Rouster S, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-6.
39. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002;15:23-9.
40. Tien PC, Grunfeld C. The fatty liver in AIDS. Semin Gastrointest Dis 2002;13:47-54.
41. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001;3:488-92.
42. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
43. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:117-25.
44. Ho TTY, Chan KCW, Wong KH, et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1736-7.
45. Martinez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
46. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
47. Eron JJ, Jr. HIV-1 protease inhibitors. Clin Infect Dis 2000;30 (Suppl 2):S160-70.
48. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.hivatis. org/guidelines/adult/Feb04_02/AdultGdl.pdf. Accessed February 14. 2002.